JPMorgan analyst Brian Cheng initiated coverage of Senti Bio with a Neutral rating and no price target. Senti is a preclinical-stage biotech company leveraging modified natural killer immune cells to treat blood and solid tumors, Cheng tells investors in a research note. The analyst believes the "next inflection point in Senti’s story is still some ways away." He awaits visibility in the translation of preclinical evidence to clinical benefits, manufacturing readiness, and product differentiation in the clinics.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNTI:
- Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
- Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
- Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
- Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
